Candel Therapeutics, Inc. is a clinical-stage biotechnology company that develops viral immunotherapies for the treatment of solid tumors. Based in Needham, Massachusetts, the company engineers viral vectors designed to stimulate anti-tumor immune responses by acting as in-situ vaccines. The company's clinical pipeline is led by CAN-2409, an off-the-shelf adenovirus-based therapy being evaluated for prostate, pancreatic, and non-small cell lung cancers. Its second lead candidate, CAN-3110, is an oncolytic herpes simplex virus being developed for recurrent high-grade glioma. In addition to its clinical assets, Candel utilizes its enLIGHTEN Discovery Platform, which leverages human biology and advanced analytics to create novel viral immunotherapy candidates. Formerly known as Advantagene, the company focuses on delivering therapeutic payloads directly into tumors to recruit and activate the immune system against cancer cells.
